E
Jasper Therapeutics, Inc. JSPR
$1.78 -$0.05-2.73% NASDAQ
Recommendation
Prev Close
$1.83
Volume
540,472
Avg Vol (90D)
565,832
Market Cap
$51.10M
Dividend & Yield
--
52-Week Range
$1.80 - $26.05
P/E (TTM)
--
EPS (TTM)
-$6.02
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
JSPR Deadline: Rosen Law Firm Urges Jasper Therapeutics, Inc. ...
11/7/2025 - GuruFocus
JSPR Deadline: Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders to Contact the Firm for Information About Their Rights
11/7/2025 - Business Wire
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights JSPR
11/7/2025 - Globe Newswire
Strong Insider Buying Reported in TMED Holdings
11/7/2025 - ETF Channel
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to ...
11/7/2025 - GuruFocus
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. ...
11/7/2025 - GuruFocus
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR
11/7/2025 - PR Newswire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
11/7/2025 - PR Newswire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. ...
11/6/2025 - GuruFocus
DEADLINE ALERT for NX, JSPR, KBR, RICK: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions
11/6/2025 - Globe Newswire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
11/6/2025 - Globe Newswire
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Jasper Therapeutics
11/6/2025 - Business Wire
Jasper Therapeutics Slides As Insider Purchases Lose Another US$89k
11/5/2025 - Simply Wall St
JSPR Deadline: JSPR Investors with Losses in Excess of $100K Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit
11/4/2025 - PR Newswire
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead ...
11/4/2025 - GuruFocus
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
11/4/2025 - PR Newswire
JSPR DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action JSPR
11/4/2025 - Globe Newswire
DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
11/4/2025 - Globe Newswire
JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
11/4/2025 - Globe Newswire
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to ...
11/4/2025 - GuruFocus
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights JSPR
11/4/2025 - Globe Newswire
Portnoy Law Firm Announces Class Action on Behalf of Jasper Therapeutics, Inc. Investors
11/4/2025 - GuruFocus
Portnoy Law Firm Announces Class Action on Behalf of Jasper Therapeutics, Inc. Investors
11/4/2025 - Globe Newswire
Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $25.63
11/4/2025 - Ticker Report
Jasper Therapeutics to Present at Upcoming Investor Conferences
11/4/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$92.73M
EBIT (TTM)
-$94.05M
Net Income (TTM)
-$90.92M
Balance Sheet
Total Assets (Q)
$46.47M
Total Debt (Q)
$2.16M
Total Liabilities (Q)
$22.97M
Book Value Per Share (Q)
$1.45
Cash Flow
Cash from Operations (TTM)
-$73.48M
Cash from Investing (TTM)
-$345.00K
Cash from Financing (TTM)
$6.52M
Net Change in Cash (TTM)
-$67.31M
Filings
Filing Date
Wednesday, August 13, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
2.47
7-Day Total Return
-24.58%
30-Day Total Return
-27.94%
60-Day Total Return
-41.25%
90-Day Total Return
-73.90%
Year to Date Total Return
-91.56%
1-Year Total Return
-92.16%
2-Year Total Return
-77.75%
3-Year Total Return
-74.93%
5-Year Total Return
-98.19%
52-week Low
Nov 04, 2025 - $1.80
52-week High
Dec 03, 2024 - $26.05
Valuation
Market Cap
$51.10M - Micro Cap
Enterprise Value
$13.75M
Price/Sales (TTM)
--
Price/Book (Q)
1.26
Dividends and Shares
Shares Outstanding
15.33
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
jaspertx.com
Phone Number
650 549 1400
Address
2200 Bridge Pkwy
Redwood City, CA 94065
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product... more
NASDAQ 11/07/2025 4:00PM Eastern Quotes delayed